GLP-1 drugs and pregnancy: what the data actually says

What's this video probably claiming?

Based on the caption and hashtag combination, @mirandaannewright appears to be sharing a personal reaction, likely surprise or concern, about being 12 weeks pregnant while having recently used a GLP-1 receptor agonist, such as semaglutide or tirzepatide. The "wow" and "serious note" framing suggests either a pregnancy discovered during active GLP-1 use, or a discussion of what that means for her and her baby. This is a scenario playing out repeatedly on TikTok right now, as GLP-1 prescriptions have surged among reproductive-age women. The video probably touches on whether continuing the medication is safe, whether it caused any complications, or whether it may have contributed to the pregnancy itself, given that some users report restored ovulation after weight loss on these drugs. Without the transcript, we can't confirm the exact angle, but the emotional framing points toward a personal disclosure with implied health implications rather than a purely informational take.

What does the science actually show?

The honest answer is that we don't have strong human safety data for GLP-1 receptor agonists in pregnancy, and that gap matters enormously. Animal studies in rats and rabbits using semaglutide showed increased fetal abnormalities and early pregnancy loss at doses relevant to human exposure, per the FDA prescribing label. The OASIS and SUSTAIN trials excluded pregnant women entirely. Novo Nordisk maintains a pregnancy registry (NCT04828382), but enrollment is ongoing and we don't have published outcome data yet. What we do have are scattered case reports and pharmacovigilance signals. A 2023 analysis in Diabetes Care (Varma et al.) flagged spontaneous abortion as a disproportionately reported adverse event in the FDA Adverse Event Reporting System for semaglutide users, though FAERS data can't establish causation. The clinical guidance from ACOG and most endocrinology societies is consistent: discontinue GLP-1 drugs at least two months before attempting conception, and stop immediately if pregnancy is discovered.

Where does the social media noise diverge from clinical reality?

Two distortions dominate GLP-1 pregnancy content on TikTok. The first is the "Ozempic baby" narrative, which frames GLP-1-related pregnancies as uniformly positive, attributing them to restored ovulation in women with PCOS or obesity. There is some biological plausibility here. Weight loss does improve ovulatory function, and insulin sensitization from GLP-1 action may help women with metabolic dysfunction conceive. But extrapolating from that mechanism to "GLP-1 makes you fertile" flattens a genuinely complicated picture. The second distortion runs the other way, with creators implying the drug definitely caused birth defects or miscarriage in their specific case. That claim is also unsupported. Miscarriage rates in the general population run 10 to 20 percent of recognized pregnancies, so individual cases don't establish causation. What's largely absent from this content is honest acknowledgment that the safety window, stopping two months before conception, exists precisely because the drug's half-life means it persists in your system. A 12-week pregnant creator who was on semaglutide recently may have had fetal exposure during organogenesis.

What should you actually know?

If you're a reproductive-age woman on a GLP-1 medication, there are a few concrete things worth knowing right now. Semaglutide has a half-life of approximately one week, meaning it takes roughly five to seven weeks to clear your system after the last dose. Tirzepatide has a similar profile. Both Novo Nordisk and Eli Lilly explicitly recommend discontinuing at least two months before a planned pregnancy. If you discover a pregnancy while actively taking these drugs, the guidance is to stop immediately and contact your OB-GYN or maternal-fetal medicine specialist, not your GLP-1 prescriber. The Pharmacovigilance Risk Assessment Committee in the EU issued a formal signal review on semaglutide and pregnancy outcomes in 2023. That review did not establish a causal link to harm, but it did prompt updated labeling. What you should not do is continue the drug because a TikTok creator seemed fine, or stop it without telling your doctor. This is a domain where individual medical advice from someone who knows your full history is not optional. FormBlends does not prescribe GLP-1 medications to pregnant patients.